A Study of TAK-505 in Adults With Solid Tumors
Public ClinicalTrials.gov record NCT07436728. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 First-in-Human, Open-Label, Dose Escalation and Expansion Trial of TAK-505 Monotherapy in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Solid tumors occur when cells in an organ or tissue (for example in the lung or liver) start growing out of control (cancer) and form a lump or mass of cells. These solid cancers may grow very far in the general area where they started (called locally advanced) or may spread to other parts of the body (called metastatic), and doctors may not always be able to completely remove them with surgery (called unresectable). This study is a first in human (or FIH) study, which means that this is the first time that the medicine, TAK-505, is given to a smaller group of adults with solid tumors of certain cancer types, such as stomach cancer (gastric adenocarcinoma), cancer of the large bowel (colorectal cancer or CRC), lung cancer (non-small lung cell cancer or NSCLC) and cancer in the mouth, throat or voice box (head and neck squamous cell carcinoma or HNSCC). The main aims of this study are to learn how safe TAK-505 is, how well it works, how well adults with solid tumors tolerate it and to find the dose of TAK-505 that works best with the least side effects. Other aims are to learn how TAK-505 moves through the body (pharmacokinetics (PK)), if it can shrink or slow cancer (preliminary antitumor activity) and to find out if it causes the body's defense system to react to it (immunogenicity).
Study identification
- NCT ID
- NCT07436728
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 151 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 10, 2026
- Primary completion
- Aug 17, 2030
- Completion
- Aug 17, 2030
- Last update posted
- May 13, 2026
2026 – 2030
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCI Health | Orange | California | 92868 | Not yet recruiting |
| University of California San Diego Medical Center, La Jolla | San Diego | California | 92093 | Not yet recruiting |
| University of California San Francisco | San Francisco | California | 94143 | Not yet recruiting |
| H Lee Moffitt Cancer Center | Tampa | Florida | 33612 | Not yet recruiting |
| Univeristy of Minnesota | Minneapolis | Minnesota | 55455 | Not yet recruiting |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | Not yet recruiting |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | Not yet recruiting |
| Sarah Cannon Research Institute SCRI | Nashville | Tennessee | 37203 | Not yet recruiting |
| Tennessee Oncology | Nashville | Tennessee | 37203 | Not yet recruiting |
| Mary Crowley Cancer Center | Dallas | Texas | 75230 | Not yet recruiting |
| Baylor College of Medicine | Houston | Texas | 77030 | Not yet recruiting |
| MD Anderson | Houston | Texas | 77030 | Not yet recruiting |
| NEXT Oncology | San Antonio | Texas | 78229 | Recruiting |
| NEXT Oncology | Fairfax | Virginia | 22031 | Recruiting |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07436728, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 13, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07436728 live on ClinicalTrials.gov.